Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis

Tumori. 2022 May 20:3008916221090323. doi: 10.1177/03008916221090323. Online ahead of print.

ABSTRACT

The treatment of castration-sensitive prostate cancer (CSPC) has been revolutionized by the advent of apalutamide and enzalutamide in this setting; however, a direct comparison between these agents is still missing. In the current paper, we performed both Number Needed to Treat (NNT) and Number Needed to Harm (NNH) analyses aimed to compare clinical outcomes in CSPC patients treated with apalutamide or enzalutamide; data from 3323 CSPC patients enrolled in the ARCHES, ENZAMET and TITAN phase III studies were included. According to our results, apalutamide showed better results in terms of overall survival (OS) and safety in patients with CSPC, while better outcomes were observed with enzalutamide in the low-volume subgroup.

PMID:35593453 | DOI:10.1177/03008916221090323